• BIBR 1532: Redefining Telomerase Inhibition for Oncology Tra

  2026-06-10

  This thought-leadership article explores BIBR 1532 as a next-generation telomerase inhibitor, examining its mechanistic impact on telomere maintenance, apoptosis induction, and c-Myc/hTERT suppression. Blending biological rationale with strategic guidance, it contextualizes BIBR 1532 within the emerging competitive landscape—especially in light of new telomere attrition strategies such as CF10/EdU synergy—and offers protocol considerations for translational researchers aiming to design impactful cancer studies.

• circDDX21 Regulates Glycolysis and Hepatocellular Carcinogen

  2026-06-10

  This study uncovers a novel mechanism by which the circular RNA circDDX21, induced by energy stress, enhances glycolysis and promotes hepatocellular carcinoma progression through stabilization of PGAM1 mRNA. The findings highlight circDDX21 as a key molecular link between metabolic adaptation and cancer growth, suggesting potential therapeutic targets for hepatocellular carcinoma.

• N-octanoyl-L-Homoserine lactone in Microbial Pathogenicity R

  2026-06-09

  Harness N-octanoyl-L-Homoserine lactone (C8-HSL) to dissect quorum-sensing driven biofilm, virulence, and host-tumor interactions with unmatched precision. Discover actionable workflows and troubleshooting strategies that translate the latest cancer–microbiota insights into robust, reproducible infection biology research.

• Canagliflozin as a Novel HDAC6 Inhibitor Against Gastric Can

  2026-06-09

  Jiang and Ma (2022) identified canagliflozin, an antidiabetic drug, as a potent HDAC6 inhibitor capable of suppressing gastric cancer cell metastasis. Their study demonstrates a drug repositioning approach using an FDA-approved bioactive compound library, revealing new therapeutic potential for canagliflozin in oncology.

• Amitriptyline HCl in Neuropharmacology: Applied Workflows &

  2026-06-08

  Amitriptyline HCl (3-(5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine hydrochloride) empowers advanced neurotransmitter receptor modulation with robust solubility and purity. This guide translates recent research and reference breakthroughs into actionable workflows, troubleshooting, and precision protocol design for mood disorder and neurodegenerative disease models.

• HyperFluor™ 488 Rabbit Anti-Goat IgG: Sensitivity in Immunoa

  2026-06-08

  The HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody is a polyclonal secondary antibody conjugated with Alexa Fluor 488, offering high sensitivity and specificity for detecting goat IgG in fluorescence-based assays. Its rigorous purification and robust performance enable reproducible results in Western blot, immunofluorescence, and flow cytometry applications.

• BGJ398 (NVP-BGJ398): Precision FGFR Inhibition in Oncology R

  2026-06-07

  BGJ398 (NVP-BGJ398) offers researchers potent, selective inhibition of FGFR1/2/3, enabling high-fidelity modulation in cancer and developmental studies. Its nanomolar potency and robust selectivity profile make it a gold-standard for dissecting FGFR signaling, optimizing both in vitro and in vivo experimental designs.

• Diethylmaleate in Redox Regulation: Protocols and Resistance

  2026-06-06

  Diethylmaleate empowers researchers to dissect cellular redox biology and insecticide resistance by enabling precise glutathione depletion and oxidative stress modeling. With robust solubility and validated impact on GST activity, it is a cornerstone reagent for toxicology, redox, and resistance studies across cell and organismal models.

• SCUBE3 Antibody Targeting Inhibits Oncogenic Signaling and I

  2026-06-05

  The reference study uncovers secretory SCUBE3 as a key driver of tumor growth, therapy resistance, and immune suppression. Antibody-mediated SCUBE3 inhibition interrupts oncogenic signaling and restores antitumor immunity, highlighting a promising pan-cancer therapeutic approach.

• GLP-1 (9-36) Amide: Redefining Antagonism for Translational

  2026-06-05

  Explore the mechanistic underpinnings and strategic value of GLP-1 (9-36) amide as a human GLP-1 receptor antagonist. This article details how recent advances in receptor signaling research are challenging assumptions about ligand selectivity and signaling specificity, and offers actionable guidance for translational researchers seeking robust metabolic models and reliable antagonism in type 2 diabetes and metabolic regulation studies. Drawing on breakthrough FRET assay findings and rigorous product validation, we position APExBIO’s GLP-1 (9-36) amide as a gold-standard tool for next-generation endocrinology and GPCR research.

• Ertugliflozin (PF-04971729): Reliable SGLT2 Inhibition for L

  2026-06-04

  This article provides an evidence-based, scenario-driven exploration of Ertugliflozin (PF-04971729) (SKU A3715) for researchers investigating cell viability, proliferation, and cytotoxicity. It addresses real-world assay challenges, protocol optimization, interpretation pitfalls, and vendor selection, demonstrating how SKU A3715 from APExBIO ensures reproducibility and selectivity in diabetes and inflammation research workflows.

• Tolazoline in Research: Advanced Assay Design and Functional

  2026-06-04

  Explore how Tolazoline, a potent α2-adrenergic receptor antagonist, enables advanced functional studies in islet and airway models. This article delivers unique guidance for assay optimization, integrating cross-receptor signaling concepts and practical protocol refinement.

• Angiotensin II Suppresses Ferroptosis to Drive NPC Radioresi

  2026-06-03

  This study identifies local angiotensin II as a key driver of radioresistance in nasopharyngeal carcinoma (NPC) by suppressing ferroptosis via the HIF-1α-HILPDA axis. The findings reveal actionable molecular targets for enhancing NPC radiosensitivity and suggest that dual targeting of Ang II signaling and ferroptosis pathways could improve radiotherapy outcomes.

• Sulfisomidine for Pertussis: Clinical Evidence, Mechanisms,

  2026-06-03

  This article examines the pivotal 1956 study evaluating sulfisomidine (sulfamethin) in the treatment of pertussis, highlighting its pharmacokinetics, safety profile, and clinical outcomes in young patients. The findings establish both the therapeutic viability and research utility of this sulfonamide, while contextualizing its broader methodological relevance for enzyme inhibition and bacterial metabolism research.

• SLC25A1 Drives Cisplatin Resistance via Senescence in HNSCC

  2026-06-02

  Li et al. reveal that SLC25A1 upregulation in head and neck squamous cell carcinoma (HNSCC) confers resistance to cisplatin therapy by promoting cellular senescence through H3K27ac-mediated gene regulation. These mechanistic insights identify SLC25A1 as a predictive biomarker and promising therapeutic target for overcoming chemoresistance.

16375 records 1/1092 page Next 12345 下5页 Last page